Haematology

Currently recruiting Monash Haematology Clinical trials

Malignant haematology View

Cancers of the blood, bone marrow and lymph nodes

Group	Disease \| Line of therapy / Setting \| Study title \| Phase \| Description	Principal Investigator
AML	AML (KMT2A/NPM1) \| Newly diagnosed, intensive chemo eligible \| Menin — 75276617ALE1001 \| Phase 3 \| Double‑blinded Bleximenib vs placebo with induction + consolidation	Dr Chyn Chua
AML	AML \| RR AML or MCL \| PEP07‑101 \| Phase 1b \| PEP07 Chk1 inhibitor monotherapy	Prof Jake Shortt
AML	AML \| CR1/CR2 or oligoblastic relapse \| Intercept — ALLG AMLM26 \| Platform (Phase 2/3 domains) \| MRD‑triggered multi‑arm precision platform	Dr Chyn Chua
AML	AML \| CR1 post induction \| CADENCE — ALLG AMLM22 \| Phase 2/3 \| Oral azacitidine vs oral azacitidine + Vididencil vaccine	Prof Jake Shortt
AML	AML \| ND AML on Ven‑Aza \| Adapt‑STOP — ALLG AMLM28 \| Phase 2 \| Randomised cessation of Ven‑Aza in MRD‑negative ND AML	Dr Chyn Chua
AML	AML/MDS/AML‑MDS \| ND & RR \| Apollo — AP30CP01 \| Phase 1 \| APL‑4098 ± azacitidine ± venetoclax	Dr Chyn Chua
AML	AML (NPM1/KMT2A) \| RR \| Menin — 75276617ALE1001 \| Phase 1/2 \| Bleximenib monotherapy	A/Prof Pasquale Fedele
MDS	MDS (IDH1+) \| Newly diagnosed \|PyramIDH — PyramIDH \| Phase 3 \| Ivosidenib vs azacitidine	Dr Chyn Chua
MDS/AML	AML/MDS \| ND/RR \| Apollo — AP30CP01 \| Phase 1 \| APL‑4098 ± azacitidine ± venetoclax	Dr Chyn Chua
MDS / MPN‑MDS	Transfusion‑dependent \| TD \| REDDS2 — REDDS2 \| Randomised feasibility \| Weekly vs usual transfusion schedule	Dr Allison Mo
CMML	CMML (TET2/RAS) \| Treatment‑naive \| PREACH‑M — PREACH‑M \| Phase 2 \| Mutation‑directed Aza + sodium ascorbate or Aza + lenzilumab	Dr Ashvind Prabahran
MPN	MF (JAK‑exposed) \| RR \| TP‑3654 — BBI‑TP3654‑102 \| Phase 1/2 \| TP‑3654 ± momelotinib (Arm 3 open)	Dr Paul Yeh
MPN	MF (suboptimal Ruxolitinib) \| Ruxolitinib inadequate response \| Navtemadlin — KRT‑232‑115 \| Phase 3 \| Navtemadlin + ruxolitinib vs placebo + ruxolitinib	Dr Paul Yeh
MPN	MF (JAK‑naive) \| ND \| Manifest‑3 — CDAK539A12303 \| Phase 3 \| Pelabresib + ruxolitinib vs placebo + ruxolitinib	Dr Paul Yeh
MPN	ET/PV/pre‑MF \| Treatment‑naive \| JBI‑802 — JBI‑802‑102 \| Phase 1/2 \| Dose‑finding JBI‑802 in thrombocytosis	Dr Paul Yeh
MPN	CML \| Previously treated \| CARDINAL — TERN‑701‑1012 \| Phase 1/2 \| Allosteric BCR::ABL1 inhibitor TERN‑701	Prof Jake Shortt
CLL/SLL	CLL \| Treatment‑naive \| BGB‑11417‑304 \| Phase 3 \| Sonrotoclax + zanubrutinib vs venetoclax + acalabrutinib	Prof Stephen Opat
CLL/SLL	CLL \| RR \| MOSUN — BO43243 \| Phase 1 \| Mosunetuzumab monotherapy or mosun + venetoclax	Prof Stephen Opat
CLL/SLL	CLL \| RR \| CELESTIAL‑RRCLL — BGB‑11417‑303 \| Phase 3 \| Sonrotoclax + anti‑CD20 vs venetoclax + rituximab	Prof Stephen Opat
CLL/SLL	CLL/SLL \| RR \| AETHER — ALLG CLL12 \| Phase 1/2 \| Venetoclax + epcoritamab (6 vs 12 cycles)	Prof Stephen Opat
CLL/SLL	CLL/SLL \| RR/TN \| BGB‑16673‑104 (Substudy 1b) \| Phase 1b/2 \| CDAC + sonrotoclax	Dr Ross Salvaris
CLL/SLL	CLL/SLL \| Post‑Ven/Obi \| MOONSHOT — ALLG CLL11 \| Phase 2 \| Epcoritamab monotherapy	Prof Stephen Opat
Indolent B-NHL	WM \| RR \| BGB‑16673‑104 (Substudy 1b) \| Phase 1b/2 \| CDAC + sonrotoclax	Dr Ross Salvaris
MCL	MCL \| RR \| PEP07‑101 \| Phase 1b \| Chk1 inhibitor monotherapy	Prof Jake Shortt
DLBCL	DLBCL \| RR \| NextGen — 95566692LYM1001 \| Phase 1 \| CD79b×CD20×CD3 trispecific antibody	Dr Ross Salvaris
DLBCL	DLBCL \| MRD‑positive post‑1L \| ALPHA‑3 — ALLO‑501A‑202 \| Phase 2 \| Cemacabtagene ansegedleucel CAR‑T	Dr Danielle Oh
B-cell NHL	DLBCL B‑cell lymphoma \| RR \| PALISADES‑1 — KT‑US‑499‑0150 \| Phase 1/2 \| KITE‑363 or KITE‑753 autologous anti‑CD19/CD20 CAR‑T therapies	Dr Danielle Oh
T‑cell NHL	Cytotoxic lymphoma / LGLL \| RR \| DR‑01 — DR‑01‑ONC‑001 \| Phase 1/2 \| DR‑01 monotherapy	Prof Jake Shortt
Myeloma	MM \| Newly diagnosed \| TRIlogy‑2 — 79635322MMY1002 \| Phase 1b \| JNJ‑79635322 + daratumumab ± IMiD	A/Prof Michael Low
Myeloma	MM \| RR (≥3 lines) \| TRIlogy‑4 — 79635322MMY3001 \| Phase 3 \| JNJ‑79635322 vs BCMA×CD3 bispecific	Dr Jeremy Er
Myeloma	MM \| RR (t(11;14)) \| BGB‑11417‑105 \| Phase 1b/2 \| Sonrotoclax + carfilzomib + dexamethasone	A/Prof Michael Low
Myeloma	MM \| RR (Len‑exposed) \| Quintessential — CA088‑1007 \| Phase 3 \| CAR‑T vs DPd/Kd	Dr Danielle Oh

Disease \| Line of therapy / Setting \| Study title \| Phase \| Description	Principal Investigator
Hereditary haemochromatosis \| Genetic iron overload \| FERROCLEAR \| Phase 2 \| Vamifeprot vs placebo	A/Prof Sanjeev Chunilal
ITP / AIHA \| RR \| INCA00585 \| Phase 2a \| Tafasitamab monotherapy	Dr Ashwini Bennett
Sickle Cell \| ND/RR \| Hibiscus‑2 \| Phase 3 \| Etavopivat vs placebo	Dr Zane Kaplan
ITP \| RR \| TAK‑079‑3002 \| Phase 3 \| Mezagitamab vs placebo	Dr Zane Kaplan
VTE \| – \| Butterfly \| Phase 2 \| LMWH via indwelling SC catheter	Dr Emma Leitinger
Hypogammaglobulinemia \| – \| Rational‑PT \| Adaptive platform \| Adaptive IG replacement/cessation/dosing	Dr Ross Salvaris

Disease \| Line of therapy / Setting \| Study title \| Phase \| Description	Principal Investigator
Blood cancers \| All AML/ALL/MPN/MM \| National Blood Cancer Registry (NBCR) \| Phase: Registry \| National registry supporting AML platform trials and blood cancer outcomes	Dr Chyn Chua
Lymphoma / CLL \| All B‑cell malignancies \| LaRDR \| Phase:Registry \| Lymphoma and Related Diseases Registry	Prof Stephen Opat
Myeloma \| All MM \| Myeloma Registry \| Phase: Registry \| National myeloma outcomes registry
Thrombotic Microangiopathy (TMA) \| TTP and other TMAs \| TMA Registry \| Phase: Registry \| National Registry for TMAs

Clinical Sciences at Monash Health

Medicine, Nursing and Health Sciences

Haematology

Currently recruiting Monash Haematology Clinical trials

Malignant haematology View

Non-malignant haematology View

Haematology registries View